Business Context and Reporting Period
This Form 10-Q covers Eli Lilly and Company for the quarter and six months ended June 30, 1998. The company operates primarily in pharmaceuticals, animal health, and health-care management (including PCS Health Systems). The reporting period reflects strong sales growth driven by new product launches and volume increases, contrasting sharply with the prior year which was distorted by a $2.4 billion asset impairment and the sale of a joint venture.
Key Financial Metrics
| Metric | Q2 1998 | Q2 1997 | 6 Mo 1998 | 6 Mo 1997 |
|---|---|---|---|---|
| Net Sales ($ millions) | $2,340.7 | $1,988.7 | $4,609.8 | $3,941.7 |
| Net Income ($ millions) | $491.3 | $(1,732.1) | $1,012.4 | $(1,299.5) |
| Earnings Per Share (Diluted) | $0.44 | $(1.57) | $0.90 | $(1.18) |
| Operating Cash Flow ($ millions) | N/A | N/A | $791.4 | $947.1 |
| Cash & Equivalents ($ millions) | $1,315.2 | N/A | $1,315.2 | $1,853.0 |
| Total Debt ($ millions) | $2,503.0 | N/A | $2,503.0 | $2,554.0 |
| Cost of Sales Margin | 26.7% | 27.6% | 26.6% | 27.7% |
Note: Q2 1997 results included a $2.4 billion non-cash asset impairment and a $618.2 million gain on the sale of DowElanco. Excluding these non-recurring items, net income increased 18% in Q2 and 17% for the six-month period compared to 1997.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 18% in Q2 and 17% for the six months ended June 30, 1998. U.S. sales grew 25% (Q2) and 22% (6 months), while international sales grew 7% (Q2) and 8% (6 months).
- Product Performance: Growth was led by Prozac (+12% Q2), Zyprexa (+$172M Q2), Gemzar (+$44M Q2), and ReoPro (+$41M Q2). Sales of anti-infectives and Axid declined due to generic competition.
- Expense Trends: Research and development expenses increased 28% in Q2 and 25% for the six months, reflecting increased investment in internal and external collaborations. Marketing and administrative expenses rose 18% (Q2) and 19% (6 months) to support new product launches and IT initiatives.
- Cash Position: Cash and cash equivalents decreased by $642 million from year-end 1997, primarily due to $864 million in stock repurchases during the first six months of 1998.
Guidance, Outlook, and Risks
- Outlook: Management expects full-year 1998 cost of sales to remain below 1997 levels. R&D expenses are projected to increase 20-22% for the full year. Humulin sales are expected to increase 3-5% for the full year. Evista sales are projected to range between $125 million and $150 million for 1998.
- Legal Contingencies: Significant litigation risks include patent challenges to Prozac by Barr Laboratories and Geneva Pharmaceuticals (trial set for January 1999). An unfavorable outcome could materially affect financial position. The company also faces ongoing product liability suits (DES, Prozac) and antitrust pricing litigation, though most costs are expected to be covered by insurance.
- Environmental: The company is a potentially responsible party for Superfund sites and has accrued approximately $325 million for environmental liabilities and litigation, with estimated insurance recoveries of $241 million.
- Year 2000: Management believes incremental costs to address Year 2000 issues will not materially affect financial position, though failure to resolve issues could impact operations.
Investor Verification Checklist
- Verify the outcome of the Prozac patent litigation against Barr and Geneva scheduled for January 1999.
- Monitor the trajectory of generic competition impacts on anti-infective and Axid sales.
- Confirm the actual full-year sales performance of new products Zyprexa, Gemzar, ReoPro, and Evista against management guidance.
- Review the status of insurance recoveries related to product liability and environmental accruals.
- Assess the impact of continued stock repurchases on liquidity and capital structure.